203 related articles for article (PubMed ID: 24258145)
1. Mammalian cell cultures for biologics manufacturing.
Kantardjieff A; Zhou W
Adv Biochem Eng Biotechnol; 2014; 139():1-9. PubMed ID: 24258145
[TBL] [Abstract][Full Text] [Related]
2. Mammalian cell culture capacity for biopharmaceutical manufacturing.
Ecker DM; Ransohoff TC
Adv Biochem Eng Biotechnol; 2014; 139():185-225. PubMed ID: 23748352
[TBL] [Abstract][Full Text] [Related]
3. Biotech drug market steadily expands.
Lawrence S
Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
[No Abstract] [Full Text] [Related]
4. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
5. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
6. The challenge of follow-on biologics for treatment of multiple sclerosis.
Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
[TBL] [Abstract][Full Text] [Related]
7. Market exclusivity for biologics.
Wheadon DE
N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
[No Abstract] [Full Text] [Related]
8. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
9. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
10. Recombinant protein therapeutics--success rates, market trends and values to 2010.
Pavlou AK; Reichert JM
Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654
[No Abstract] [Full Text] [Related]
11. Security market reaction to FDA fast track designations.
Anderson CW; Zhang Y
J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
[TBL] [Abstract][Full Text] [Related]
12. 2004 approvals: the demise of the blockbuster?
Frantz S
Nat Rev Drug Discov; 2005 Feb; 4(2):93-4. PubMed ID: 15756752
[No Abstract] [Full Text] [Related]
13. The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495494
[TBL] [Abstract][Full Text] [Related]
14. 3 New Biologics To Be Worth $14B in Sales by 2019.
Adams KT
Manag Care; 2015 May; 24(5):36-7. PubMed ID: 26117964
[No Abstract] [Full Text] [Related]
15. Market watch: Top drugs and companies by sales in 2017.
Urquhart L
Nat Rev Drug Discov; 2018 Mar; 17(4):232. PubMed ID: 29588516
[No Abstract] [Full Text] [Related]
16. Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy.
Chen D
Adv Biochem Eng Biotechnol; 2014; 139():167-83. PubMed ID: 23719711
[TBL] [Abstract][Full Text] [Related]
17. Satisfaction guaranteed--"payment by results" for biologic agents.
Garber AM; McClellan MB
N Engl J Med; 2007 Oct; 357(16):1575-7. PubMed ID: 17942870
[No Abstract] [Full Text] [Related]
18. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
Obradovic M; Mrhar A; Kos M
Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
[TBL] [Abstract][Full Text] [Related]
19. Hybrid and disposable facilities for manufacturing of biopharmaceuticals: pros and cons.
Ravisé A; Cameau E; De Abreu G; Pralong A
Adv Biochem Eng Biotechnol; 2009; 115():185-219. PubMed ID: 19623478
[TBL] [Abstract][Full Text] [Related]
20. Market watch: Sales of biologics to show robust growth through to 2013.
Goodman M
Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
[No Abstract] [Full Text] [Related]
[Next] [New Search]
